Pharmacological Intervention View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2015

AUTHORS

Masamichi Takano

ABSTRACT

Ischemic heart disease is a life-threatening disorder; especially acute coronary syndrome (ACS) is a major cause of death in the world. Coronary arteries of angiographic significant stenosis with patients’ symptoms or certified myocardial ischemia are generally administered by revascularization therapies, such as coronary artery bypass surgery and percutaneous coronary intervention using balloon angioplasty or metallic stent deployment. However, ACS often arises from mild to moderate stenosis without the evidence of myocardial ischemia in a brief period. Accurate prospect of ACS is therefore complicated at the present, and pharmacological intervention as preventive insurance is extremely important. Among medical treatment for coronary risk factors, lipid-lowering therapy represented by administration of HMG-CoA reductase inhibitor (statin) is the most powerful, practical, and established way to prevent against ACS. From an angioscopic point of view, morphological changes in atherosclerotic coronary plaque focused on lipid-lowering intervention are reviewed in this chapter. More... »

PAGES

217-227

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-4-431-55546-9_19

DOI

http://dx.doi.org/10.1007/978-4-431-55546-9_19

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052904092


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, 270-1694, Inzai, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416273.5", 
          "name": [
            "Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, 270-1694, Inzai, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takano", 
        "givenName": "Masamichi", 
        "id": "sg:person.0611573717.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611573717.76"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015", 
    "datePublishedReg": "2015-01-01", 
    "description": "Ischemic heart disease is a life-threatening disorder; especially acute coronary syndrome (ACS) is a major cause of death in the world. Coronary arteries of angiographic significant stenosis with patients\u2019 symptoms or certified myocardial ischemia are generally administered by revascularization therapies, such as coronary artery bypass surgery and percutaneous coronary intervention using balloon angioplasty or metallic stent deployment. However, ACS often arises from mild to moderate stenosis without the evidence of myocardial ischemia in a brief period. Accurate prospect of ACS is therefore complicated at the present, and pharmacological intervention as preventive insurance is extremely important. Among medical treatment for coronary risk factors, lipid-lowering therapy represented by administration of HMG-CoA reductase inhibitor (statin) is the most powerful, practical, and established way to prevent against ACS. From an angioscopic point of view, morphological changes in atherosclerotic coronary plaque focused on lipid-lowering intervention are reviewed in this chapter.", 
    "editor": [
      {
        "familyName": "Mizuno", 
        "givenName": "Kyoichi", 
        "type": "Person"
      }, 
      {
        "familyName": "Takano", 
        "givenName": "Masamichi", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-4-431-55546-9_19", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-4-431-55545-2", 
        "978-4-431-55546-9"
      ], 
      "name": "Coronary Angioscopy", 
      "type": "Book"
    }, 
    "keywords": [
      "acute coronary syndrome", 
      "myocardial ischemia", 
      "pharmacological interventions", 
      "coronary artery bypass surgery", 
      "coronary risk factors", 
      "lipid-lowering therapy", 
      "artery bypass surgery", 
      "lipid-lowering interventions", 
      "percutaneous coronary intervention", 
      "ischemic heart disease", 
      "HMG-CoA reductase inhibitors", 
      "life-threatening disorder", 
      "atherosclerotic coronary plaques", 
      "coronary syndrome", 
      "bypass surgery", 
      "coronary intervention", 
      "revascularization therapy", 
      "patient's symptoms", 
      "balloon angioplasty", 
      "coronary artery", 
      "significant stenosis", 
      "coronary plaques", 
      "heart disease", 
      "risk factors", 
      "moderate stenosis", 
      "medical treatment", 
      "stent deployment", 
      "reductase inhibitors", 
      "major cause", 
      "intervention", 
      "stenosis", 
      "ischemia", 
      "therapy", 
      "symptoms", 
      "morphological changes", 
      "brief period", 
      "angioplasty", 
      "surgery", 
      "artery", 
      "syndrome", 
      "plaques", 
      "disease", 
      "administration", 
      "disorders", 
      "death", 
      "treatment", 
      "inhibitors", 
      "cause", 
      "evidence", 
      "insurance", 
      "period", 
      "factors", 
      "changes", 
      "present", 
      "point", 
      "view", 
      "chapter", 
      "world", 
      "way", 
      "prospects", 
      "deployment"
    ], 
    "name": "Pharmacological Intervention", 
    "pagination": "217-227", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052904092"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-4-431-55546-9_19"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-4-431-55546-9_19", 
      "https://app.dimensions.ai/details/publication/pub.1052904092"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_134.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-4-431-55546-9_19"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55546-9_19'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55546-9_19'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55546-9_19'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55546-9_19'


 

This table displays all metadata directly associated to this object as RDF triples.

125 TRIPLES      22 PREDICATES      85 URIs      78 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-4-431-55546-9_19 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author Nb4ea8ab8de60422f84014235524fb917
4 schema:datePublished 2015
5 schema:datePublishedReg 2015-01-01
6 schema:description Ischemic heart disease is a life-threatening disorder; especially acute coronary syndrome (ACS) is a major cause of death in the world. Coronary arteries of angiographic significant stenosis with patients’ symptoms or certified myocardial ischemia are generally administered by revascularization therapies, such as coronary artery bypass surgery and percutaneous coronary intervention using balloon angioplasty or metallic stent deployment. However, ACS often arises from mild to moderate stenosis without the evidence of myocardial ischemia in a brief period. Accurate prospect of ACS is therefore complicated at the present, and pharmacological intervention as preventive insurance is extremely important. Among medical treatment for coronary risk factors, lipid-lowering therapy represented by administration of HMG-CoA reductase inhibitor (statin) is the most powerful, practical, and established way to prevent against ACS. From an angioscopic point of view, morphological changes in atherosclerotic coronary plaque focused on lipid-lowering intervention are reviewed in this chapter.
7 schema:editor Neebe614c1db94c32ac4a34b6c63688af
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N19c0caefc47942d4a17a95b1525f28ba
11 schema:keywords HMG-CoA reductase inhibitors
12 acute coronary syndrome
13 administration
14 angioplasty
15 artery
16 artery bypass surgery
17 atherosclerotic coronary plaques
18 balloon angioplasty
19 brief period
20 bypass surgery
21 cause
22 changes
23 chapter
24 coronary artery
25 coronary artery bypass surgery
26 coronary intervention
27 coronary plaques
28 coronary risk factors
29 coronary syndrome
30 death
31 deployment
32 disease
33 disorders
34 evidence
35 factors
36 heart disease
37 inhibitors
38 insurance
39 intervention
40 ischemia
41 ischemic heart disease
42 life-threatening disorder
43 lipid-lowering interventions
44 lipid-lowering therapy
45 major cause
46 medical treatment
47 moderate stenosis
48 morphological changes
49 myocardial ischemia
50 patient's symptoms
51 percutaneous coronary intervention
52 period
53 pharmacological interventions
54 plaques
55 point
56 present
57 prospects
58 reductase inhibitors
59 revascularization therapy
60 risk factors
61 significant stenosis
62 stenosis
63 stent deployment
64 surgery
65 symptoms
66 syndrome
67 therapy
68 treatment
69 view
70 way
71 world
72 schema:name Pharmacological Intervention
73 schema:pagination 217-227
74 schema:productId N08149734515541f189ad0c89dc7158db
75 N6be068d9dd264aa7842678f542ee3505
76 schema:publisher N47e3e2947f8f44a0a47e813cf2dfc392
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052904092
78 https://doi.org/10.1007/978-4-431-55546-9_19
79 schema:sdDatePublished 2022-10-01T06:52
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N2c127f03149d4a64a2fe07e205c12f55
82 schema:url https://doi.org/10.1007/978-4-431-55546-9_19
83 sgo:license sg:explorer/license/
84 sgo:sdDataset chapters
85 rdf:type schema:Chapter
86 N08149734515541f189ad0c89dc7158db schema:name doi
87 schema:value 10.1007/978-4-431-55546-9_19
88 rdf:type schema:PropertyValue
89 N19c0caefc47942d4a17a95b1525f28ba schema:isbn 978-4-431-55545-2
90 978-4-431-55546-9
91 schema:name Coronary Angioscopy
92 rdf:type schema:Book
93 N2c127f03149d4a64a2fe07e205c12f55 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N47e3e2947f8f44a0a47e813cf2dfc392 schema:name Springer Nature
96 rdf:type schema:Organisation
97 N6be068d9dd264aa7842678f542ee3505 schema:name dimensions_id
98 schema:value pub.1052904092
99 rdf:type schema:PropertyValue
100 N879a8130b0424d46918aac6e621566aa rdf:first N91586b97ad634270996c2fb324a9bbdd
101 rdf:rest rdf:nil
102 N91586b97ad634270996c2fb324a9bbdd schema:familyName Takano
103 schema:givenName Masamichi
104 rdf:type schema:Person
105 Nb4ea8ab8de60422f84014235524fb917 rdf:first sg:person.0611573717.76
106 rdf:rest rdf:nil
107 Ne0051c73c9334cbab375576336a4b352 schema:familyName Mizuno
108 schema:givenName Kyoichi
109 rdf:type schema:Person
110 Neebe614c1db94c32ac4a34b6c63688af rdf:first Ne0051c73c9334cbab375576336a4b352
111 rdf:rest N879a8130b0424d46918aac6e621566aa
112 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
113 schema:name Medical and Health Sciences
114 rdf:type schema:DefinedTerm
115 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
116 schema:name Cardiorespiratory Medicine and Haematology
117 rdf:type schema:DefinedTerm
118 sg:person.0611573717.76 schema:affiliation grid-institutes:grid.416273.5
119 schema:familyName Takano
120 schema:givenName Masamichi
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611573717.76
122 rdf:type schema:Person
123 grid-institutes:grid.416273.5 schema:alternateName Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, 270-1694, Inzai, Chiba, Japan
124 schema:name Cardiovascular Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, 270-1694, Inzai, Chiba, Japan
125 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...